Erasca, Inc.
Public company- Headquarters
- SAN DIEGO, California
- Ticker
- ERAS
- CIK
- 0001761918
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| COONicholas (Nik) Chetwyn, Ph.D. | Oct 16, 2026 | Departed |
| President, Research & DevelopmentCharles S. Fuchs, M.D., M.P.H. | Aug 10, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive departure
COO departs: Nicholas (Nik) Chetwyn, Ph.D.
Nicholas (Nik) Chetwyn, Ph.D., Chief Operating Officer of Erasca, Inc., leaves the role, effective November 2, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: Chief Operating Officer
- Executive appointment
President, Research & Development appointed: Charles S. Fuchs, M.D., M.P.H.
Charles S. Fuchs, M.D., M.P.H. was named President, Research & Development of Erasca, Inc., effective August 10, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 10, 2026Role: President, Research & Development
Last verified Nov 8, 2026